Lilly's tirzepatide kidney disease trial in overweight and obesity marked completed
A 134-person Phase 2 study of tirzepatide in people with overweight or obesity and chronic kidney disease has finished, but no kidney outcomes data are public yet.
Eli Lilly's Phase 2 trial of tirzepatide in people with overweight or obesity and chronic kidney disease, with or without type 2 diabetes, has been marked completed, according to a registry change logged on September 11, 2026 [1].
The same entry shows two other adjustments. The date listed for the study moved up to July 6, 2026, from September 2026, about two months earlier, and planned enrollment was cut from 140 to 134 participants [1]. The trial is registered as NCT05536804 and is sponsored by Eli Lilly [1][2].
The change from "active, not recruiting" to "completed" means the study has stopped enrolling and following participants [1]. Neither record says whether the trial met its goals. The primary outcome measures, any kidney-related results, and how tirzepatide compared with placebo have not been reported [1][2]. The registry also does not explain why enrollment dropped by six people or why the date moved up [1].
Tirzepatide is the molecule in Mounjaro and Zepbound. The trial enrolled adults with overweight or obesity and chronic kidney disease, with or without type 2 diabetes, a group in which kidney decline is a central concern [1][2]. Kidney outcomes are an active area of research across this drug class: the same monitoring log lists a Phase 2 study at University Medical Center Groningen of finerenone plus semaglutide for albuminuria in chronic kidney disease, with 41 participants [1]. Semaglutide is the molecule in Ozempic, Wegovy and Rybelsus.
The log also shows a Phase 3 master protocol of orforglipron in obstructive sleep apnea and obesity marked completed, with planned enrollment raised from 600 to 712 participants [1]. These logs exist because ClinicalTrials.gov overwrites a record when it changes and keeps no public history of the previous value [1].
Why it matters for patients
Whether tirzepatide protects kidney function, reduces albuminuria or changes the risk of kidney failure is not yet known from these records [1][2]. A completed trial is not the same as a successful one. Until results are posted, the status change alone says nothing about benefit or harm, and no finding from this study has been reported [1][2].
At 134 participants, this was a Phase 2 study, a size generally used to look for signals rather than to set treatment standards [1]. Whether Lilly plans a larger trial in kidney disease, and whether it has discussed a kidney indication with the FDA, has not been disclosed [1][2]. The registry change does not include any change to currently approved uses of tirzepatide, and none has been reported [1][2].
What happens next
Under the reporting rules described in the registry, sponsors generally submit results within one year of a trial's primary completion date, though extensions and certifications can delay posting [2]. The date now listed for this study is July 6, 2026, which would point toward a results posting in mid-2027 at the latest [1][2]. Whether Lilly will post results on that schedule, post them earlier or seek a delay has not been disclosed [1][2].
Kidney research in the class continues on other tracks. The Groningen finerenone-plus-semaglutide study appears in the same log with 41 participants; what it found has not been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.